FIBROGEN INC License Agreements
10 Contracts & Agreements
- Amendment No. 1 to the Second Amended and Restated Exclusive License Agreement, dated as of November 16, 2023 (Filed With SEC on February 26, 2024)
- Amended and Restated Exclusive License Agreement by and among FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd., and Eluminex Biosciences Suzhou) Limited,... (Filed With SEC on August 7, 2023)
- Amended and Restated Exclusive License Agreement by and between FibroGen, Inc. and Eluminex Biosciences (Suzhou) Limited as of January 21, 2022 (Filed With SEC on May 9, 2022)
- Exclusive License Agreement by and between FibroGen, Inc. and Eluminex Biosciences (Suzhou) Limited as of July 16, 2021 (Filed With SEC on November 9, 2021)
- Exclusive License and Option Agreement by and between FibroGen, Inc. and HiFiBiO (HK) Limited (D.B.A. HiFiBiO Therapeutics), as of June 16, 2021 (Filed With SEC on August 9, 2021)
- Amendment No. 1 to the Amended and Restated License, Development and Commercialization Agreement by and between FibroGen, Inc. and AstraZeneca AB, effective as of July 1, 2020 (Filed With SEC on August 6, 2020)
- Second Amended and Restated License, Development and Commercialization Agreement by and among FibroGen China Anemia Holdings, Ltd., FibroGen China Medical Technology Development... (Filed With SEC on August 6, 2020)
- AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (for the US and Certain Other Territories) between FIBROGEN, INC. and ASTRAZENECA AB (Filed With SEC on November 12, 2014)
- AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (CHINA) between FIBROGEN CHINA ANEMIA HOLDINGS, LTD.; BEIJING FIBROGEN MEDICAL TECHNOLOGY DEVELOPMENT... (Filed With SEC on October 23, 2014)
- AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (for the US and Certain Other Territories) between FIBROGEN, INC. and ASTRAZENECA AB (Filed With SEC on October 20, 2014)
